证券代码：002432 证券简称：九安医疗 公告编号：2025-044 天津九安医疗电子股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 特别提示： 1、天津九安医疗电子股份有限公司（以下简称"公司"）2024年年度权益 分派方案为：按公司总股本474,281,172股，扣除公司已回购股份45,025,516股， 以429,255,656股为基数，向全体股东每10股派2.00元人民币现金（含税），不转 增不送股，共计派发85,851,131.20元。 2、本次权益分派实施后，按公司总股本折算每股现金分红比例及除权除息 参考价如下： 考虑到公司回购专用证券账户上的股份不参与 2024 年年度权益分派，公司 本 次 实 际 现 金 分 红 的 总 金 额 = 实 际 参 与 分 配 的 总 股 本 × 分 配 比 例 ， 即 85,851,131.20 元=429,255,656 股×0.2 元/股；每股现金红利=现金分红总额÷总股 本（包含已回购股份），即 0.1810131 元/股=85,851,13 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a decline of 1.26% recently, reflecting broader market trends in the healthcare sector [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,370.1 points with a trading volume of 11.048 billion yuan [1]. - Over the past month, the index has increased by 2.41%, but it has decreased by 7.73% over the last three months and is down 1.09% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.6%), Aier Eye Hospital (8.13%), and United Imaging Healthcare (7.77%) among others [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.46%) and the Shanghai Stock Exchange (39.54%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, and Tianhong China Securities Index Healthcare Equipment and Services ETF [2].

地址：北京市朝阳区光华路正大中心北塔 11-12 层 邮编：100020 电话：010-65876666 传真：010-65876666-6 北京中银律师事务所 关于天津九安医疗电子股份有限公司 2024 年年度股东大会之 法律意见书 二〇二五年五月 法律意见书 北京中银律师事务所 关于天津九安医疗电子股份有限公司 2024 年年度股东大会之 法律意见书 致：天津九安医疗电子股份有限公司 北京中银律师事务所（以下简称"本所"）接受天津九安医疗电子股份有限 公司（以下简称"公司"）的委托，指派见证律师出席公司 2024 年年度股东大 会（以下简称"本次股东大会"）进行法律见证，并依据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、《上 市公司治理准则》（以下简称"《治理准则》"）等法律、法规和规范性文件以 及《天津九安医疗电子股份有限公司章程》（以下简称"《公司章程》"）的规 定就公司本次股东大会的召集、召开程序、出席会议人员的资格、表决程序、表 决结果等有关事宜出具法律意见书。 本所律师依据法律意 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-043 天津九安医疗电子股份有限公司 现场会议时间：2025年5月21日下午14:00 网络投票时间：2025年5月21日，其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月21日上 午9:15至9:25，9:30至11:30和下午13:00至15:00。 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 二、会议召开情况 1、召开时间： 通过深圳证券交易所互联网投票的具体时间为：2025年5月21日上午9:15至 下午3:00的任意时间。 2、现场召开地点：天津市南开区雅安道金平路三号天津九安医疗电子股份 有限公司会议室 3、召开方式：本次会议采取现场投票与网络投票相结合 4、召集人：公司董事会 5、主持人：董事长、总经理刘毅先生 6、会议的召集、召开符合《公司法》《证券法》《深圳证券交易所股票上 市规则》《上市公司股东大会规则》等有关 ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

64只个股今日获机构买入型评级，天味食品最新评级被调高，10股机构首次关注。 证券时报·数据宝统计显示，今日机构研报共发布66条买入型评级记录，共涉及64只个股。雷赛智能、 通威股份等关注度最高，均有2次机构买入型评级记录。 今日获机构买入型评级个股中，共有15条评级记录中对相关个股给出了未来目标价。以公布的预测目标 价与最新收盘价进行对比显示，共有7股上涨空间超20%，通威股份上涨空间最高，5月19日国泰海通预 计公司目标价为25.37元，上涨空间达49.41%，上涨空间较高的个股还有九安医疗、天味食品等，上涨 空间分别为42.89%、36.40%。 从机构评级变动看，今日机构买入型评级记录中，有10条评级记录为机构首次关注，涉及爱旭股份、汇 纳科技等10只个股。 | 000829 | 天音控股 | 1 | 1.71 | | 商贸零售 | | --- | --- | --- | --- | --- | --- | | 000830 | 鲁西化工 | 1 | -0.09 | 12.55 | 基础化工 | | 002080 | 中材科技 | 1 | 3.81 | 18.95 | 建筑材料 | | 002202 ...

Company Overview - Dezhou Jiusi Electronic Technology Co., Ltd. has been established with a registered capital of 500,000 yuan [1] - The legal representative of the company is Li Kang [1] - The company is wholly owned by Jiuan Medical [1] Business Scope - The business scope includes a wide range of services and products such as technology services, equipment sales, and retail of various consumer goods [1] - Specific areas of operation include sales of communication equipment, broadcasting equipment, computer hardware and software, home appliances, and various retail items [1] - The company is also involved in medical device sales, advertising services, and market consulting [1] Regulatory Compliance - The company is permitted to operate under various licenses, including retail of publications and medical devices, as well as value-added telecommunications services [1] - Operations are subject to approval from relevant authorities, and specific business activities will be conducted based on the necessary permits [1]

Core Viewpoint - The medical device industry in 2024 faces a complex policy environment and market challenges, with a slight revenue growth of 0.19% but a significant decline in net profit by 13.82%, indicating a divergence in performance across different sub-sectors [1][13]. Medical Equipment - The medical equipment sector experienced a revenue decline of 1.38% and a net profit drop of 17.93% in 2024, with Q1 2025 showing a further revenue decrease of 5.27% and a net profit decline of 14.10% [3][10]. - The decline is attributed to slowed bidding processes and inventory digestion, particularly affecting imaging and monitoring equipment [3][4]. - Leading company, United Imaging Healthcare, reported a revenue of 10.3 billion yuan in 2024, a decrease of 9.73%, marking the first decline in net profit in six years [3][4]. High-Value Consumables - The high-value consumables sector saw a revenue growth of 3.58% but a net profit decline of 4.09% in 2024, with Q1 2025 showing a slight revenue increase of 0.25% and a net profit drop of 6.15% [6][7]. - The sector is impacted by price pressures from national procurement policies, but domestic market share for local brands is improving [6][7]. Low-Value Consumables - The low-value consumables sector achieved a revenue growth of 12.86% and a remarkable net profit increase of 114.83% in 2024, with Q1 2025 showing a revenue growth of 2.37% and a net profit growth of 7.19% [8][9]. - The growth is driven by recovery in the domestic market and accelerated international expansion, particularly in mid-to-high-end markets [8][9]. In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 6.13% and a net profit drop of 47.04% in 2024, with Q1 2025 showing a further revenue decrease of 15.39% and a net profit decline of 40.27% [10][11]. - The decline is largely due to the high base effect from the COVID-19 pandemic and the impact of various policies, including DRGs and procurement policies [10][11]. Conclusion - The overall revenue growth in the medical device industry is stable, but profit volatility is significant, particularly in the in vitro diagnostics and medical equipment sectors. However, growth drivers remain in low-value consumables' international expansion and innovation, high-value consumables' technological updates, and the gradual recovery of medical equipment [13][14].

Group 1 - The core viewpoint of the articles highlights that Jiuan Medical's stock closed at 38.38 yuan, down 1.03%, with a rolling PE ratio of 10.76 times and a total market value of 18.159 billion yuan [1] - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, placing Jiuan Medical at the 32nd position in the industry ranking [1] - On May 15, Jiuan Medical experienced a net outflow of 336,400 yuan in principal funds, with a total outflow of 19.2729 million yuan over the past five days [1] Group 2 - Jiuan Medical focuses on the research, production, and sales of home medical devices, as well as cloud platform systems and services, gradually transforming into an Internet + medical solution provider [1] - The company's main products include Health series products, non-self-branded products, traditional hardware products, Internet medical products and services, and new retail business [1] - In the latest quarterly report for Q1 2025, Jiuan Medical reported an operating income of 507 million yuan, a year-on-year decrease of 33.49%, and a net profit of 266 million yuan, a year-on-year increase of 7.62%, with a gross profit margin of 70.46% [1]